Labcorp offers first FDA-cleared Alzheimer's blood test for 55-plus patients

Labcorp will offer the Elecsys pTau-217 blood test, the first FDA-cleared single-biomarker assay to rule in or rule out Alzheimer's amyloid pathology across care settings.

Labcorp will offer the Elecsys pTau-217 blood test, the first FDA-cleared single-biomarker assay to rule in or rule out Alzheimer's amyloid pathology in patients 55 and older across primary and specialty care.

"The best advances in Alzheimer's disease testing should make the diagnostic process simpler, more accessible and more consistent for both patients and clinicians," Dr. Brian Caveney, chief medical and scientific officer at Labcorp, said.

The test, developed by Roche Diagnostics, measures phosphorylated Tau 217, a protein that indicates amyloid pathology — a hallmark of Alzheimer's disease. It uses the same clinically validated cutoffs across primary and specialty care settings, reporting positive, intermediate and negative result categories. Labcorp said performance is comparable to cerebrospinal fluid testing and positron emission tomography imaging, but requires only a standard blood draw at a physician's office or one of Labcorp's more than 2,200 patient service centers nationwide.

The launch gives Labcorp a foothold in the growing Alzheimer's diagnostic market as blood-based biomarkers gain traction over invasive CSF testing and costly PET scans. The test joins Labcorp's existing portfolio, which includes the FDA-cleared Elecsys pTau-181 and the Lumipulse pTau-217/Beta-Amyloid 42 Ratio, and will be available nationwide in the coming months.

Standardization across care settings

For many patients experiencing cognitive decline, evaluation for Alzheimer's disease has historically involved multiple tests, care settings and healthcare providers. While several pTau-217 assays are commercially available, standardization across care settings has been a concern for clinicians. The Elecsys pTau-217 test provides a single, standardized assay with the same clinically validated cutoffs across both primary and specialty care, supporting a consistent approach to patient assessment.

The FDA clearance follows a broader push toward blood-based biomarkers in neurology. Quest Diagnostics, a direct competitor, has also announced plans to offer the Roche pTau217 test, indicating that the major diagnostic labs are moving in tandem to bring Alzheimer's blood testing into mainstream clinical practice. Results from the Elecsys pTau-217 are intended to be interpreted alongside clinical information and other relevant findings as part of a full evaluation.

Investor implications

Labcorp, which employs nearly 71,000 people across approximately 100 countries and performed more than 750 million tests for patients worldwide, is expanding its neurology diagnostics footprint at a time when the global Alzheimer's disease diagnostics market is expected to grow substantially as the population ages. The company supported more than 85 percent of the new drugs and therapeutic products approved by the FDA in 2025, giving it a broad platform to cross-sell its expanding diagnostic menu.

The Alzheimer's blood test market represents a significant opportunity for Labcorp and its peers. With the Elecsys pTau-217 offering performance comparable to CSF testing and PET imaging at a fraction of the cost and invasiveness, adoption could accelerate as primary care physicians gain access to a standardized, FDA-cleared tool. The test's availability across both primary and specialty care settings could meaningfully expand the addressable patient population for Alzheimer's screening.

For investors, the key question is whether the market has already priced in the Alzheimer's diagnostics opportunity for Labcorp. The company's existing neurology portfolio, combined with the new Elecsys pTau-217 offering, gives it a path to benefit from earlier and broader patient identification — a trend that could also support Alzheimer's therapeutic developers who rely on accurate patient screening.

This article is for informational purposes only and does not constitute investment advice.